Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | LYL797 |
Synonyms | |
Therapy Description |
LYL797 is a chimeric antigen receptor T-cell (CAR-T) therapy that targets ROR1, potentially resulting in antitumor activity against ROR1-expressing tumors (Cancer Res (2022) 82 (12_Supplement): 2754). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
LYL797 | LYL-797|LYL 797 | LYL797 is a chimeric antigen receptor T-cell (CAR-T) therapy that targets ROR1, potentially resulting in antitumor activity against ROR1-expressing tumors (Cancer Res (2022) 82 (12_Supplement): 2754). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT05274451 | Phase I | LYL797 | A Study to Investigate LYL797 in Adults with Solid Tumors | Active, not recruiting | USA | 0 |